Genevoyager

Genevoyager Focuses on Gene Therapy Technology Innovation, Committed to Developing Large-Scale Viral Vector Preparation and Delivery Technologies, Providing One-Stop CRO and CDMO Services for Gene Therapy. The Company Boasts a Highly Professional Team, with Master's, Doctoral, and Technical Staff Accounting for 70%. Its Subsidiaries Include: Wuhan Neuromatech Co., Ltd.: A CRO Technology Platform That Has Provided Over 20,000 Customized Gene Therapy Services in the Past 8 Years.Rui Zheng PharmaTech (Wuhan) Co., Ltd.: A CDMO Technology Platform with an Exclusive Global Patent Portfolio for the Insect Baculovirus One-Bac 4.0 System, Enabling Large-Scale Production of High-Activity, High-Fill-Rate AAV Vector Gene Therapy Drugs, with a Single Batch Capacity Reaching 1E+18vg.Our Mission: Focusing on Gene Therapy Technology Innovation, Collaborating to Accelerate and Reduce Costs in Gene Therapy Drug R&D and Manufacturing, Benefiting Society.